Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Head
Hangzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Head Biopharma is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for metabolic diseases. The company's primary focus is on targeting the incretin system, including GLP-1, GIP, and Glucagon receptors, to treat conditions such as type 2 diabetes, obesity, and NASH. Their lead programs include oral small molecule GLP-1 receptor agonists designed to provide more convenient and effective alternatives to injectable therapies. Head Biopharma leverages its expertise in medicinal chemistry to optimize the pharmacological profiles of its candidates for metabolic health.
- Therapeutic areas
- EndocrinologyGastroenterologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Head.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Head.